Table 5.
KRAS gene mutation for each tumor type, with or without mucin or MSI
| Tumor Type | Odds Ratio In Situ versus Cancer | 95% Confi-dence Interval | P-value | Interaction effect | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Adenomas* | In situ cancer† | Cancer‡ | ||||||||
|
| ||||||||||
| Ki-ras | No. | Mutated | No. | Mutated | No. | Mutated | ||||
| n (%) | n (%) | n (%) | ||||||||
| Total | 134 | 83 (61.9) | 84 | 57 (67.8) | 171 | 54 (31.6) | 4.6 | 2.6-8.0 | <0.0001§ | |
| Mucinous status | ||||||||||
| Non-mucinous | - | - | 63 | 46 (73.0) | 137 | 40 (29.2) | 6.6 | 3.4-12.9 | <0.0001§ | 0.01 |
| Mucinous | - | - | 21 | 11 (52.4) | 31 | 14 (45.2) | 1.3 | 0.4-4.1 | 0.6 | |
| Microsatellite status | ||||||||||
| Microsatellite stable | - | - | 73 | 52 (71.2) | 141 | 50 (35.5) | 4.5 | 2.4-8.3 | <0.0001§ | 0.4 |
| Microsatellite unstable | - | - | 6 | 1 (16.7) | 26 | 3 (11.5) | 1.5 | 0.1-18.0 | 0.7 | |
*
0Adenomas vs. Cancers: O.R. = 3.5, C.I. = 2.2 – 5.7 p = <0.0001.
†
5 in situ cancers not assayed for microsatellite instability.
‡
3 cancers not assayed for mucin.
§
denotes statistical significance.